Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ATYR vs CGTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATYR Captures Overall Composite Edge (34.3 SELL vs 56.1 HOLD), While CGTX Leads 3–1 on Growth & Valuation Pillars

ATYR Overall Winner 6-Pillar Tally: ATYR 1 – 3 CGTX (2 Tie) Matrix Metrics: ATYR 1 – 4 CGTX

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Cognition Therapeutics, Inc. (CGTX) on higher Unified Composite conviction (34.3/100 SELL vs. 56.1/100 HOLD) after splitting the core matrix 1–4 (led by Options & Positioning), while CGTX wins 3–1 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.96 (N/M Forward P/E, 0.0% operating margin) versus CGTX at $0.63 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CGTX currently prints a higher short-term Unified Composite Score (56.1/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (1–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.9); meanwhile CGTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ATYR vs CGTX
ATYR NASDAQ Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.96
-5.34% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.67β · 13806% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (391.6% over 20 days), RSI 58
RSI-14: 57.9 · SMA20: $4.36 · SMA50: $1.93
CGTX NASDAQ
Cognition Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.63
-1.44% 1D
Market Cap $64.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.57β · 64% Vol
Unified Composite Score
56.1 / 100 HOLD
Tech 38.0 Fund 49.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.5%), weak momentum, RSI 32
RSI-14: 32.2 · SMA20: $0.69 · SMA50: $0.83

6-Pillar Scorecard Institutional Category Breakdown (ATYR 1 – 3 CGTX)

Columns: Metric · ATYR · CGTX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CGTX
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $15.6M $64.6M
3. Profitability & Quality CGTX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -93.7% -48.6%
4. Balance Sheet & Cash Flow CGTX
Cash Generation (TTM) N/A -$20M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.9M Net Cash $31M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATYR
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 154.5% (36th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ATYR (1) vs CGTX (4)
Institutional Metric ATYR CGTX Criterion Row Edge
Market Capitalization
Scale
$15.6M $64.6M Larger Scale CGTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-93.7% -48.6% Higher ROE CGTX
52-Week Range Position
Momentum
62% ($0–$8) 6% ($1–$2) Stronger Trend ATYR
Beta / 30D Volatility
Risk Regime
-9.67β · 13806% Vol 2.57β · 64% Vol Lower Realized Risk CGTX
Unified Institutional Score
Composite Signal
34.3 / 100 (SELL) 56.1 / 100 (HOLD) Higher Composite CGTX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($4.9M Net Cash) -$20M ($31M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATYR +2802.21 pp
ATYR: +2788.76% · CGTX: -13.45%
3M Horizon ATYR +866.61 pp
ATYR: +830.93% · CGTX: -35.68%
6M Horizon ATYR +970.2 pp
ATYR: +926.92% · CGTX: -43.28%
1Y Horizon ATYR +618.08 pp
ATYR: +558.7% · CGTX: -59.38%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATYR vs CGTX. Trailing 12-month operating profitability (ATYR 0.0% vs CGTX 0.0%) and valuation multiples (ATYR N/M vs CGTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ATYR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-93.7% · N/M
CGTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-48.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ATYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 154.5%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CGTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ATYR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CGTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $64.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ATYR vs CGTX Key Questions & Quantitative Answers

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Cognition Therapeutics, Inc. (CGTX) on higher Unified Composite conviction (34.3/100 SELL vs. 56.1/100 HOLD) after splitting the core matrix 1–4 (led by Options & Positioning), while CGTX wins 3–1 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.96 (N/M Forward P/E, 0.0% operating margin) versus CGTX at $0.63 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CGTX currently prints a higher short-term Unified Composite Score (56.1/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (1–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.9); meanwhile CGTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGTX leads the Growth & Scale pillar: ATYR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CGTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ATYR generates N/A in USD-normalized revenue versus N/A for CGTX. In operating R&D and SG&A reinvestment, ATYR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CGTX.

ATYR and CGTX trade at balanced relative valuation multiples. ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CGTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATYR (-93.7% ROE) versus CGTX (-48.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk). By comparison, CGTX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.57β · 64% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.